Show results for
Refine by
Locations
- USA
- Alabama
- Alaska
- Arizona
- Arkansas
- California
- Colorado
- Connecticut
- Delaware
- District Of Columbia
- Florida
- Georgia (Us)
- Hawaii
- Idaho
- Illinois
- Indiana
- Iowa
- Kansas
- Kentucky
- Louisiana
- Maine
- Maryland
- Massachusetts
- Michigan
- Minnesota
- Mississippi
- Missouri
- Montana
- Nebraska
- Nevada
- New Hampshire
- New Jersey
- New Mexico
- New York
- North Carolina
- North Dakota
- Ohio
- Oklahoma
- Oregon
- Pennsylvania
- Rhode Island
- South Carolina
- South Dakota
- Tennessee
- Texas
- Utah
- Vermont
- Virginia
- Washington
- West Virginia
- Wisconsin
- Wyoming
Tumor Infiltrating Suppliers In Usa
12 companies found
based inMinneapolis, MINNESOTA (USA)
Bio-Techne empowers researchers in Life Science and Clinical Diagnostics by providing high-quality reagents, instruments, custom manufacturing, and testing services. Our family of brands creates a unique portfolio of products and services. Science ...
Immune cell therapy is rapidly emerging as an important alternative for cancer treatment, as well as treatment of autoimmune disease. Also known as adoptive cell therapy or cellular immunotherapy, it supercharges an individual’s immune ...
based inPalo Alto, CALIFORNIA (USA)
Immune-Onc is a clinical-stage company developing a novel class of myeloid checkpoint inhibitors. We believe myeloid checkpoints are the next frontier of immunotherapy for cancer. In collaboration with scientists, our research team is among the ...
Immune-Onc’s lead program is IO-202, an antagonist antibody targeting the myeloid checkpoint LILRB4 (also known as ILT3). Immune-Onc has a Phase I trial underway to evaluate IO-202 as a potential treatment for acute myeloid leukemia (AML) and ...
based inBoston, MASSACHUSETTS (USA)
At PathAI, we’re dedicated to improving patient outcomes with reliable AI-Powered technology and meaningful collaboration with biopharma, laboratories, and clinicians — aiming to provide patients with access to accurate diagnoses and effective ...
PathExploreTM offers unprecedented spatial and cellular resolution of the tumor microenvironment (TME) from H&E images. PathExplore is an AI-powered panel of histopathology features that spatially characterize the tumor microenvironment (TME) ...
based inCarlsbad, CALIFORNIA (USA)
TargaZyme is a clinical-stage biotechnology company based in San Diego, CA and focused on the research and development of disruptive and novel, off-the-shelf T-Cell products that are aimed at improving the efficacy of T-cell therapies by delivering ...
TILs are part of the body’s natural response to cancer:The cells of the immune system perform immunosurveillance while circulating throughout the bodyAs part of the normal immune response, TIL migrate to the tumor site through recognition of ...
based inMorrisville, NORTH CAROLINA (USA)
Istari Oncology, Inc., is a clinical-stage biotechnology company developing innovative immunotherapies for the treatment of patients with solid tumors. Istari has built a passionate and experienced leadership team focused on clinical trial strategy ...
The tumor environment contains all the ingredients needed to mount an anticancer immune response—tumor antigens, antigen presenting cells (APCs, including tumor-associated macrophages [TAMs] and dendritic cells), and T cells—but ...
based in, MASSACHUSETTS (USA)
MtoZ Biolabs is an integrate contract research organization (CRO) providing advanced proteomics, metabolomics, bioinformatics, and biopharmaceutical analysis services to researchers in biochemistry, biotechnology, and biopharmaceutical fields. The ...
T cells play a vital role in destroying pathogens and monitoring pathological cells. They are able to distinguish between self-antigens and non-self-antigens by surface T cell receptors (TCRs). Most human T cells express the classical TCRs, which ...
based inUtrecht, NETHERLANDS
At LAVA, we are focused on applying our expertise in gamma-delta T cell engagers. We are building a pipeline of gamma-delta bsTCEs that have applications in both solid and hematologic malignancies. Our lead program, LAVA-051, targets the tumor ...
Vγ9Vδ2 T cells belong to the first line of defense against cancer and have the potential to elicit deep and durable responses in the ...
based inMonmouth Junction, NEW JERSEY (USA)
MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet ...
Andecaliximab is a recombinant chimeric IgG4 monoclonal antibody (mAb) targets matrix metalloproteinase 9 (MMP9). Andecaliximab shows the antifibrotic efficacy in idiopathic pulmonary fibrosis mouse models. Andecaliximab can be used for the research ...
based inBroomfield, COLORADO (USA)
Founded in 2009, Flagship Biosciences, Inc., is a technology-driven spatial biology and biomarker services company delivering the most accurate and informative data available. We are revolutionizing biomarker analysis to improve drug development and ...
For rapid and precise cancer care, pathologists and oncologists need dependable diagnostic testing to connect patients to individualized immuno-oncology therapies. Flagship’s TissueInsight® diagnostic service offers you access to robust, ...
based inHackensack, NEW JERSEY (USA)
At Champions Oncology, we are passionate about aiding the pharmaceutical industry in developing the innovative treatments of today and the cures for tomorrow. We provide end-to-end research and development solutions throughout the drug development ...
Champions Oncology's ex vivo 3D co-culture platform for Immuno-Oncology therapeutic testing. Champions Oncology has launched an innovative new platform enabling Immuno-Oncology researchers the ability to test their therapeutics in a 3D organoid ...
based inCambridge, MASSACHUSETTS (USA)
We are a group of individuals who know that there is a better way to develop drugs. Our business model and broad, science-based portfolio has attracted some of the brightest minds in drug development. Our team brings together more than 300 years of ...
BOS-342 is a bispecific antibody comprised of an anti-GPC3 antagonistic antibody linked to a 4-1BB (CD137) agonistic anticalin ...
based inTuebingen, GERMANY
Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation ...
Immatics is developing Adoptive Cell Therapies, which are designed to leverage the power of T cells to actively infiltrate tumor tissue and kill tumor cells in a specific and serial ...